Sign In
Buy URGN
$38.24
-2.85 (-6.94%)
At Close: Jul 31, 2026
Lost Money on UroGen Pharma Ltd. (URGN)? Urged to Join Class Action Before July 28, 2025 - Contact Levi & Korsinsky
10:15pm, Monday, 02'nd Jun 2025
NEW YORK CITY, NY / ACCESS Newswire / June 2, 2025 / If you suffered a loss on your UroGen Pharma Ltd. (NASDAQ:URGN) investment and want to learn about a potential recovery under the federal securitie
UROGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against UroGen Pharma Ltd.
09:00pm, Monday, 02'nd Jun 2025
NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against UroGen Pharma
Lost Money on UroGen Pharma Ltd. (URGN)? Contact Levi & Korsinsky to Join Class Action Before July 28, 2025
04:30pm, Monday, 02'nd Jun 2025
NEW YORK, NY / ACCESS Newswire / June 2, 2025 / If you suffered a loss on your UroGen Pharma Ltd. (NASDAQ:URGN) investment and want to learn about a potential recovery under the federal securities law
SAN FRANCISCO, June 02, 2025 (GLOBE NEWSWIRE) -- A securities class action lawsuit styled Cockrell v. UroGen Pharma Ltd.
URGN STOCK ALERT: UroGen Pharma Ltd. Shareholders with Losses may have been Affected by Fraud - Contact BFA Law
03:46pm, Monday, 02'nd Jun 2025
NEW YORK CITY, NY / ACCESS Newswire / June 2, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against UroGen Pharma Ltd. (NASDAQ:URGN) and certain
URGN LAWSUIT ALERT: Levi & Korsinsky Notifies UroGen Pharma Ltd. Investors - Lead Plaintiff Deadline July 28, 2025
02:30pm, Monday, 02'nd Jun 2025
NEW YORK, NY / ACCESS Newswire / June 2, 2025 / If you suffered a loss on your UroGen Pharma Ltd. (NASDAQ:URGN) investment and want to learn about a potential recovery under the federal securities law
Class Action Lawsuit Filed: UroGen Pharma Ltd. (URGN) - Join by July 28, 2025 - Contact Levi & Korsinsky
02:15pm, Monday, 02'nd Jun 2025
NEW YORK, NY / ACCESS Newswire / June 2, 2025 / If you suffered a loss on your UroGen Pharma Ltd. (NASDAQ:URGN) investment and want to learn about a potential recovery under the federal securities law
NEW YORK CITY, NY / ACCESS Newswire / June 2, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against UroGen Pharma Ltd. ("UroGen" or the "Company") (NASDAQ:URGN).
Levi & Korsinsky Urges UroGen Pharma Ltd. (URGN) Shareholders to Act Before Lead Plaintiff Deadline July 28, 2025
02:00pm, Monday, 02'nd Jun 2025
NEW YORK, NY / ACCESS Newswire / June 2, 2025 / If you suffered a loss on your UroGen Pharma Ltd. (NASDAQ:URGN) investment and want to learn about a potential recovery under the federal securities law
SAN DIEGO, CA / ACCESS Newswire / June 2, 2025 / Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired UroGen Pharma Ltd. (NASDAQ:UR
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN
01:27pm, Monday, 02'nd Jun 2025
NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDAQ: URGN). Such investor
Deadline Approaching: UroGen Pharma Ltd. (URGN) Investors Who Lost Money Urged To Contact Law Offices of Howard G.
12:00pm, Monday, 02'nd Jun 2025
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming July 28, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who pur
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today hi
Investors Urged to Contact Levi & Korsinsky for Information Before July 28, 2025 - UroGen Pharma Ltd. (URGN)
10:15am, Monday, 02'nd Jun 2025
NEW YORK, NY / ACCESS Newswire / June 2, 2025 / If you suffered a loss on your UroGen Pharma Ltd. (NASDAQ:URGN) investment and want to learn about a potential recovery under the federal securities law
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, tod
